SAN DIEGO, March 31, 2020 – Primmune Therapeutics announced today that it has selected PRTX007 as its lead clinical development candidate for SARS-CoV-2 (the virus that causes COVID-19) and for oncology indications. “PRTX007 is an oral small molecule that specifically...
SAN DIEGO, March 2, 2020 – Primmune Therapeutics today announced that it has raised $7 million in seed financing to support the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists for long-term systemic activation of innate...
Appleman JR, Webber SE. Pharmacodynamic response in vitro and in vivo of novel orally administered Toll-like Receptor 7 agonists for systemic immunotherapy of cancer. In: 34th Annual Meeting and Pre-conference Programs of the Society for Immunotherapy of Cancer (SITC...
SAN DIEGO, November 6, 2019 – Primmune Therapeutics today announced that it will present primate pharmacology data on PRX034 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2019 in National Harbor, MD. PRX034 is a novel orally bioavailable small...
Appleman JR, Webber SE. Discovery of a series of novel toll-like receptor 7 agonists for systemic immunotherapy of cancer. In: Proceedings of the American Association for Cancer Research AACR Annual Meeting; 2019 March 29-April 3, Atlanta, GA, Abstract 3262. To...
